2021年5月24日 · MC903 at 5 nmol/10 μl was applied to both auricles of human PD-1 knock-in mice. Simultaneously, 500 μg of anti-human PD-1 antibody was administered intraperitoneally (Day 0). The same doses of MC903 and anti-human PD-1 antibody were respectively swabbed and administered every 3 days from Day 0 to Day 27.

2023年2月4日 · 向人pd-1敲入小鼠的耳廓涂敷mc903诱导变态反应性皮炎时，同时施用hm266时，耳廓的肿胀被显著抑制(图11)。 此时变态反应性炎症反应的抑制值得关注，如血中ige浓度的显著减少、耳廓组织中浸润的嗜酸性粒细胞数目、进一步通过小鼠的搔抓行为的减少所见。

2023年1月13日 · Anti–hPD-1 agonist mAbs with enhanced FcγRIIB binding were further confirmed to suppress allogeneic human T cell responses to primary B cells from other individuals. The addition of HM266-hIgG1-X2, HM266-hIgG1-X3, and HM266-hIgG1-X4 to the mixed lymphocyte reaction strongly suppressed IFN-γ production .

mc903即 卡泊三醇 ，是一种维生素d3的低钙类似物，广泛用于治疗银屑病。研究发现，局部使用mc903可激发小鼠上皮角质细胞高表达tslp，促进cd4+t细胞向th2细胞分化及激活并释放炎症细胞因子，引起小鼠产生特应性皮炎表型。

HM266 induces PD-1-mediated immunosuppression based on Fc receptor binding. To prevent Fc receptor binding, HM266-mIgG1 was pretreated with endoS, which hydrolyzes Fc glycan. DO11.10 cells expressing human PD-1 were stimulated with FcγRIIB+ IIA1.6 cells. IL-2 levels in response to OVA323-339 were determined. Data represent average ± SE (n = 3 ...

We have developed an effective treatment method for inflammatory diseases such as type I allergy and eosinophil disease mediated by Th2 cells, targeting PD-1, which is an immunoregulatory molecule.

2023年1月25日 · In a mouse model of acute graft-versus-host disease induced by transfer of spleen cells from C57BL/6 human PD-1 knock-in mice to B6D2F1 mice, HM266 (mIgG1) treatment reduced the expansion of H-2b + H-2d-donor-derived T cells – many of which were hPD-1 + – in host mice, and prevented body weight loss.

诱导原理： mc903诱导角化细胞产生tslp，并激活2型先天性淋巴细胞以及th2细胞产生过量的细胞因子。 数据展示： 与G1对照组相比，G2造模组小鼠耳部皮肤组织增厚，疾病评分增加，证明MC903能够成功诱导小鼠皮炎表型。

2024年8月21日 · mc903，也称为卡泊三醇，是一种活性维生素 d 类似物，主要用于治疗牛皮癣。 有趣的是，据观察，它的副作用是在一些牛皮癣患者中引起刺激性皮肤炎症。

2023年1月26日 · Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.